Abstract
A new series of N-(4-chlor-2-methylphenoxy)ethyl- (1-6) and N-(4-chlor-2-methylphenoxy)acetylaminoalkanols (7-10) has been synthesized for evaluation of their anticonvulsant activity. Pharmacological tests included maximal electroshock seizure (MES) and subcutaneous pentylenetetrazole seizure (ScMet) assays, as well as rotarod for neurotoxicity (TOX) and were performed in mice i.p. and rats p.o. The activity of the compounds in the group was various, and the most active compound in mice was R,S-1N-[(4-chlor-2-methylphenoxy)ethyl]aminopropan-2-ol, revealing 100% activity in MES test at 30 mg/kg b.w., 0.5 h after administration without toxicity at the same dose and time. In rats (p.o.), the most active compound was 2N-[(4-chlor-2-methylphenoxy)ethyl]amino-2-methylpropan-1-ol, revealing 25% activity in MES at 30 mg/kg b.w. 0.5 and 1 h after administration.
Keywords: Alkanolamides, Aminoalkanols, Anticonvulsant, Epilepsy, Seizures, Synthesis, MES, Rotorod, neurotransmitter systems, lamotrigine
Letters in Drug Design & Discovery
Title:Synthesis and Evaluation of Anticonvulsant Activity of Some N-[(4-Chlor- 2-methylphenoxy)ethyl]- and N-[(4-Chlor-2-methylphenoxy)acetyl]aminoalkanols
Volume: 10 Issue: 1
Author(s): Anna M. Waszkielewicz, Edward Szneler, Marek Cegla and Henryk Marona
Affiliation:
Keywords: Alkanolamides, Aminoalkanols, Anticonvulsant, Epilepsy, Seizures, Synthesis, MES, Rotorod, neurotransmitter systems, lamotrigine
Abstract: A new series of N-(4-chlor-2-methylphenoxy)ethyl- (1-6) and N-(4-chlor-2-methylphenoxy)acetylaminoalkanols (7-10) has been synthesized for evaluation of their anticonvulsant activity. Pharmacological tests included maximal electroshock seizure (MES) and subcutaneous pentylenetetrazole seizure (ScMet) assays, as well as rotarod for neurotoxicity (TOX) and were performed in mice i.p. and rats p.o. The activity of the compounds in the group was various, and the most active compound in mice was R,S-1N-[(4-chlor-2-methylphenoxy)ethyl]aminopropan-2-ol, revealing 100% activity in MES test at 30 mg/kg b.w., 0.5 h after administration without toxicity at the same dose and time. In rats (p.o.), the most active compound was 2N-[(4-chlor-2-methylphenoxy)ethyl]amino-2-methylpropan-1-ol, revealing 25% activity in MES at 30 mg/kg b.w. 0.5 and 1 h after administration.
Export Options
About this article
Cite this article as:
M. Waszkielewicz Anna, Szneler Edward, Cegla Marek and Marona Henryk, Synthesis and Evaluation of Anticonvulsant Activity of Some N-[(4-Chlor- 2-methylphenoxy)ethyl]- and N-[(4-Chlor-2-methylphenoxy)acetyl]aminoalkanols, Letters in Drug Design & Discovery 2013; 10 (1) . https://dx.doi.org/10.2174/1570180811309010035
DOI https://dx.doi.org/10.2174/1570180811309010035 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Disrupted Structural Brain Network in AD and aMCI: A Finding of Long Fiber Degeneration
Current Alzheimer Research The NMDA Receptor/Ion Channel Complex: A Drug Target for Modulating Synaptic Plasticity and Excitotoxicity
Current Pharmaceutical Design Genomic and Pharmacogenomic Biomarkers of Parkinson’s Disease
Current Drug Metabolism Mitogenomics: Recognizing the Significance of Mitochondrial Genomic Variation for Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Modulators of Voltage-Dependent Calcium Channels for the Treatment of Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Cardiac ATP-Sensitive Potassium Channels: A Potential Target for an Anti-Ischaemic Pharmacological Strategy
Cardiovascular & Hematological Agents in Medicinal Chemistry A Hidden Pandemic? Abuse of Gabapentinoids: A Brief Review of Recent Studies
Current Drug Research Reviews Voltage-Dependent Na+ Channels as Targets of BACE1 - Implications for Neuronal Firing and Beyond
Current Alzheimer Research Molecular Properties Prediction, Docking Studies, and Antimicrobial Screening of 1,3,4-Thiadiazole and s-Triazole Derivatives
Current Computer-Aided Drug Design ABC Transporters in the CNS – An Inventory
Current Pharmaceutical Biotechnology N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer’s Disease, Vascular Dementia and Parkinson’s Disease
Current Alzheimer Research Spatiotemporal Modulation of Central Neural Pathway Underlying Acupuncture Action: A Systematic Review
Current Medical Imaging GluN2B/N-methyl-D-aspartate Receptor Antagonists: Advances in Design, Synthesis, and Pharmacological Evaluation Studies
CNS & Neurological Disorders - Drug Targets Development, Recent Achievements and Current Directions of Research into GABA Uptake Inhibitors
Current Medicinal Chemistry Current Use of mTOR Inhibitors for the Treatment of Subependymal Giant Cell Astrocytomas and Epilepsy in Patients with TSC
Current Medicinal Chemistry Simultaneous Determination of Cytochrome P450 Oxidation Capacity in Humans: A Review on the Phenotyping Cocktail Approach
Current Pharmaceutical Biotechnology Calpain-1 and Calpain-2 in the Brain: Dr. Jekill and Mr Hyde?
Current Neuropharmacology Inhibition Profiling of Urease and Carbonic Anhydrase II by High- Throughput Screening and Molecular Docking Studies of Structurally Diverse Organic Compounds
Letters in Drug Design & Discovery [General Articles] Cannabinoids: Mechanisms and Therapeutic Applications in the CNS
Current Medicinal Chemistry Editorial (Thematic Issue: Neuroinflammation a Common Link in Neurodegenerative Neurological and Psychiatric Disorders)
Current Pharmaceutical Design